Heterocyclic compounds as CCR5 antagonists

A compound of formula (I)

• or a pharmmaceutically acceptable derivative thereof, wherein:
• X is a C1-5 alkylene chain, wherein said X is optionallly substituted by one or more ═O, ═S, —S(O)t—, alkyl, or halogen
• Ring A is a saturated 8-membered monocyclic ring having one ring nitrogen and 0-heteroatoms;
• Ring B has an oxygen atom in addition to the depicited nitrogen;
• R1 is phenyl optionally substituted by one or more R6;
• each R2 is independently selected from the group consistingt of —OR0, —C(O)—R0, —S(O)2—R0, —C(O)—N(R0)2, —S(O)2—N(R0)2, —(CH2)a—N(R0)(—Vb—R+), —(CH2)a—(—Vb—R+), halogen, alkyl optionally substituted by one or more R7, alkenyl optionally substituted by one or more R7, alkynl optionally substituted by one or more R7, aryl optionally substituted by one or more R6, heteroaryl optionally substituted by R6, cycloalkyl optionally substituted by one or more R8, and heterocyclyl optionally substituted by one or more R8;
• and two adjacent R2s on Ring A are optionally taken together to form a fused, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen;
• or two geminal R2s are optionally taken together to form a spiro, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen, said fused or spiro ring being optionally substituted by one or more R8;
• each a independently is 0-3;
• each b independently is 0 or 1;
• V is —C(O)—, —C(O)O—, —S(O)2—, or —C(O)—N(R0)—;
• R+ is alkyl, cycloalkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, or heterocyclyl, wherein said R+ is optionally substituted by one or more R8;
• m is 0 or 1;
• n is 0-5;
• R3 is H, —N(R0)2, —N(R0)C(O)R0, —CN, halogen, CF3, alkyl optionally substituted by one or more groups selected from R7 or —S-aryl optionally substituted by
• —(CH2)1-6—N(R0)SO2(R0), alkenyl optionally substituted by one or more groups selected from R7 or —S-aryl optionally substituted by —(CH2)1-6—N(R0)SO2(R0), alkynyl optionally substituted by one or more groups selected from R7 or —S-aryl optionally substituted by —(CH2)1-6—N(R0)SO2(R0), cycloalkyl or carbocyclyl optionally substituted by one or more R8, aryl optionally substituted by one or more R6, heteroaryl optionally substituted by one or more R6, or heterocyclyl optionally substituted by one or more R8;
• Y is —C(O)—,
• each t independently is 1 or 2;
• each R6 is independently selected from the group consisting of halogen, —CF3, —OCF3, —OR0, —(CH2)1-6—OR0, —SR0, —(CH2)1-6SR0, —SCF3, —R0, methylenedioxy, ethylenedioxy, —NO2, —CN, —(CH2)1-6—CN, —N(R0)2, —(CH2)1-6—N(R0)2, —NR0C(O)R0, —NR0(CN), —NR0C(O)N(R0)2, —NR0C(S)N(R0)2, —NR0—CO2R0, —NR0NR0C(O)R0, —NR0NR0C(O)N(R0)2, —NR0NR0CO2R0, —C(O)C(O)R0, —C(O)CH2C(O)R0, —(CH2)0-6CO2R0, —O—C(O)R0, —C(O)R0, —C(O)N(R0)N(R0)2, —C(O)N(R0)2, —C(O)N(R0)OH, —C(O)N(R0)SO2R0, —OC(O)N(R0)2, —S(O)tR0, —S(O)t—OR0, —S(O)tN(R0)C(O)R0, —S(O)tN(R0)OR0, —NR0SO2N(R0)2, —NR0SO2R0, —C(═S)N(R0)2, —C(═NH)—N(R0)2, —(CH2)1-6—C(O)R0, —C(═N—OR0)—N(R0)2, —O—(CH2)0-6—SO2N(R0)2, —(CH2)1-6NHC(O)R0, and —SO2N(R0)2 wherein the two R0s on the same nitrogen are optionally taken together to form a 5-8 membered saturated, partially saturated, or aromatic ring having additional 0-4 heteroatoms selected from oxygen, phosphorus, nitrogen, or sulfur;
• each R7 is independently selected from the group consisting of halogen, —CF3, —R0, —OR0, —OCF3, —(CH2)1-6—OR0, —SR0, —SCF3, —(CH2)1-6—SR0, aryl optionally substituted by R6, methylenedioxy, ethylenedioxy, —NO2, —CN, —(CH2)1-6—CN, —N(R0)2, —(CH2)1-6—N(R0)2, —NR0C(O)R0, —NR0(CN), —NR0C(O)N(R0)2, —N(R0)C(S)N(R0)2, —NR0CO2R0, —NR0NR0C(O)R0, —NR0NR0C(O)N(R0)2, —NR0NR0CO2R0, —C(O)C(O)R0, —C(O)CH2C(O)R0, —(CH2)0-6—CO2R0, —C(O)R0, —C(O)N(R0)N(R0)2, —C(O)N(R0)2, —C(O)N(R0)OH, —OC(O)R0, —C(O)N(R0)SO2R0, —OC(O)N(R0)2, —S(O)tR0, —S(O)t—OR0, —S(O)tN(R0)C(O)R0, —S(O)tN(R0)OR0, —NR0SO2N(R0)2, —NR0SO2R0, —C(═S)N(R0)2, —C(═N H)—N(R0)2, —(CH2)1-6—C(O)R0, —C(═N—OR0)—N(R0)2, —O—(CH2)0-6—SO2N(R0)2, —(CH2)1-6—NHC(O)R0, and —SO2N(R0)2 wherein the two R0s on the same nitrogen are optionally taken together to form a 5-8 membered saturated, partially saturated, or aromatic ring having additional 0-4 heteroatoms selected from oxygen, phosphorus, nitrogen, or sulfur;
• each R8 is independently selected from R7, ═O, ═S, ═N(R0), and ═N(CN);
• each R0 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carbocyclylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl, wherein each member of R0 except H is optionally substituted by one or more R*, OR*, N(R*)2, ═O, ═S, halo, CF3, NO2, CN, —C(O)R*, —CO2R*, —C(O)-aryl, —C(O)-heteroaryl, —C(O)-aralkyl, —S(O)t-aryl, —S(O)t-heteroaryl, —NR*SO2R*, —NR*C(O)R*, —NR*C(O)N(R*)2,—N(R*)C(S)N(R*)2, —NR*CO2R*, —NR*NR*C(O)R*, —NR*NR*C(O)N(R*)2, —NR*NR*CO2R*, —C(O)C(O)R*, —C(O)CH2C(O)R*, —C(O)N(R*)N(R*)2, —C(O)N(R*)2, —C(O)NR*SO2R*, —OC(O)N(R*)2, —S(O)tR*, —NR*SO2N(R*)2, and —SO2N(R*)2 wherein the two R*s on the same nitrogen are optionally taken together to form a 5-8 membered saturated, partially saturated or aromatic ring having additional 0-4 heteroatoms selected from oxygen, phosphorus, nitrogen or sulfur;
• and
• each R* is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl.